Physician

Sam Stea

According to 2025 Medicare claims, Sam Stea (NPI: 1053396994) practices nephrology in the Williamsport, PA market, with the plurality of this provider's patient population coming from Lycoming, PA. This provider's primary affiliated billing organization is SUSQUEHANNA PHYSICIAN SERVICES (NPI: 1477793172; TIN: 232449454) and primary practice location at 17701-1965. Stea is affiliated with the Keystone ACO (ACO ID: A1552), participating under the MSSP model.

Stea's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 581 traditional Medicare patients, billed 1,482 HCPCS/CPT codes, and received $170,862 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 5,526 prescription claims across 889 beneficiaries totaling $329,776 in drug costs, led by Veltassa (Patiromer Calcium Sorbitex). DME data shows 367 claims. Open Payments data shows 14 records totaling $343. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $311,046 to $170,862. Similarly, Part D prescription costs have declined steadily, from $728,337 to $329,776. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,339 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	689	6,324	$311,046
2016	762	4,965	$333,209
2017	899	6,885	$404,510
2018	1,104	9,586	$546,856
2019	1,104	8,906	$541,190
2020	975	4,518	$314,717
2021	910	4,529	$347,615
2022	684	2,297	$232,712
2023	628	1,591	$156,629
2024	581	1,482	$170,862

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	596	5,351	$728,337
2016	574	4,882	$584,718
2017	618	5,636	$652,078
2018	758	7,171	$567,782
2019	771	6,377	$455,629
2020	748	5,610	$402,741
2021	787	5,685	$490,682
2022	819	5,454	$395,043
2023	867	5,439	$362,413
2024	889	5,526	$329,776

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	51	359	$21,878
2016	63	502	$24,208
2017	75	608	$28,400
2018	74	694	$25,964
2019	61	727	$21,975
2020	49	644	$17,781
2021	14	436	$11,456
2022	24	422	$8,720
2023	N/R	351	$8,011
2024	11	367	$12,693

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	49	194	$266
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	98	98	$113
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	393	730	$86
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	81	149	$60
81003	Automated urinalysis test	62	62	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Veltassa	Patiromer Calcium Sorbitex	30	1,685	$51,887
Jardiance	Empagliflozin	25	1,350	$25,883
Renvela	Sevelamer Carbonate	18	612	$25,705
Prosol	Parenteral Amino Acid 20% No.1	91	635	$15,195
Sevelamer Carbonate	Sevelamer Carbonate	77	3,370	$9,948

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	11	$6,986
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	11	99	$1,788
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	94	$1,063
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	89	$1,053
J7520	Sirolimus, oral, 1 mg	N	N/R	23	$757

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	14	$343	Vifor Pharma, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sam Stea?

Tedicare shows public-source Medicare data for Sam Stea (NPI 1053396994), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sam Stea have ACO affiliation data?

Sam Stea is shown with ACO affiliation data for Keystone ACO (MSSP, ACO ID A1552).

What billing organization is linked to Sam Stea?

Sam Stea is linked to SUSQUEHANNA PHYSICIAN SERVICES (billing NPI 1477793172) in the available physician profile data.

Does Sam Stea have Open Payments data?

Sam Stea has 14 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.